Open AccessSynergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer
Author(s) -
Chia-Hao Liu,
Yen-Hsuan Kung,
Jeff Lin,
Chi-Mu Chuang,
Hsiang Ling Wu,
Lingyu Jiang,
Ying-Chu Shih,
Peng-Hui Wang,
Yi Jen Chen
Publication year - 2021
Publication title -
journal of the chinese medical association
Language(s) - English
Resource type - Journals
eISSN - 1728-7731
pISSN - 1726-4901
DOI - 10.1097/jcma.0000000000000629
Subject(s) - medicine , bevacizumab , cervical cancer , cisplatin , proportional hazards model , chemotherapy , oncology , progression free survival , clinical endpoint , adverse effect , cancer , gastroenterology , surgery , clinical trial
Cisplatin-based chemotherapy (CBC) is highly efficacious for advanced cervical cancer; its efficacy can be enhanced by combining with 15 mg/kg (standard dose) bevacizumab (BEV). However, this standard dose is associated with various adverse events (AEs). Therefore, in this retrospective study, we analyzed the survival outcomes and AEs in patients with advanced or recurrent cervical cancer treated with CBC in combination with BEV 7.5 mg/kg.